The diagnosis of small round cell tumors always has been extremely difficult, and our current classification systems continue to evolve. Since its initial discovery by Dr James Ewing, the historical context of what is acceptably included under the designation "Ewing sarcoma" has changed. Although Ewing sarcoma and primitive neuroectodermal tumor were both initially described in the early 20th century, these tumors were considered likely distinct entities until the end of that same century, almost 75 years later. With modern immunohistochemistry and more recent advances in molecular techniques, the understanding of Ewing sarcoma and Ewing-like tumors has improved dramatically but also raises new questions and challenges. We now know that this category of tumors is remarkably more heterogenous than initially thought, especially in regards to its cytogenetics and molecular properties, and some of these differences likely have prognostic relevance. Whether we are now expanding the spectrum of Ewing sarcoma or simply recognizing new entities is controversial. Therapeutic approaches to address these new categories and/or entities need further focus and attention. Herein, we provide a comprehensive historical perspective on Ewing sarcoma, Ewing-like tumors (CIC and BCOR-rearranged sarcomas), and related and/or similar small round cell tumors, often included in the differential diagnosis, including mesenchymal chondrosarcoma, desmoplastic small round cell tumor, and small cell osteosarcoma. We also seek to provide updates and insights into the evolving classification and clinical relevance of the Ewing family of tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PAP.0000000000000203 | DOI Listing |
Rofo
January 2025
University Medical Center Rostock, Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock, Germany.
Cureus
December 2024
Department of Orthopaedics and Traumatology, Cerrahpasa Faculty of Medicine, Istanbul University - Cerrahpasa, Istanbul, TUR.
Extraskeletal Ewing sarcoma (EES) is a rare and aggressive malignancy originating in soft tissues, distinct from osseous Ewing sarcoma. It commonly affects adolescents and young adults but can occur at any age. Due to its rarity and overlapping clinical features with other malignancies, EES poses significant diagnostic and therapeutic challenges.
View Article and Find Full Text PDFSkeletal Radiol
January 2025
Department of Radiology, Moffit Cancer Center Florida, Tampa, FL, USA.
The sacrum can harbor a diverse group of both benign and malignant tumors, including metastases. Primary tumors of the sacrum can arise from bone, cartilage, marrow, notochordal remnants, or surrounding nerves and vessels. Among a variety of primary tumors of the spine, chordoma, germ cell tumors and Ewing's sarcoma are recognized for their propensity to occur in the sacrum.
View Article and Find Full Text PDFJBJS Case Connect
January 2025
Department of Orthopaedic Surgery, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.
Case: Triple pelvic osteotomy (TPO) is used to treat developmental dysplasia of the hip in a pediatric population. This case report highlights a new indication for this procedure. Acetabular coverage was restored in a 9-year-old patient who experienced instability following hip hemiarthroplasty and proximal femur composite allograft implantation for the treatment of Ewing sarcoma.
View Article and Find Full Text PDFEcancermedicalscience
November 2024
Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh 160030, India.
Background: There is limited data from India on Ewing sarcoma (ES) patients. We analysed the demographic and clinical profile of ES patients, the systemic chemotherapy, local treatment and outcomes in patients with localised, metastatic and recurrent disease.
Methods: Data of ES patients reporting from 2010 to 2019 to a tertiary care referral centre in north India was evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!